ENvue Medical Secures $2.5M Investment by Amending Preferred Stock Terms

summarizeSummary

ENvue Medical amended its Series H Convertible Preferred Stock terms, removing the floor price in exchange for a $2.5 million additional investment, significantly boosting its capital.

check_boxKey Events

• Material Agreement Amendment

  The company entered into an Amendment Agreement with holders of its Series H Convertible Preferred Stock on January 30, 2026.

• Removal of Preferred Stock Floor Price

  The amendment removes the 'Floor Price' from the Certificate of Designations for the Series H Convertible Preferred Stock, potentially allowing for conversion at lower prices.

• Significant Capital Infusion

  In consideration for the amendment, the preferred stockholders exercised an 'Additional Investment Right' of $2,500,000, providing substantial new capital to the company.

auto_awesomeAnalysis

ENvue Medical, a micro-cap company, has secured a substantial $2.5 million capital injection by agreeing to amend the terms of its Series H Convertible Preferred Stock. This amendment removes the 'Floor Price' for conversion, which could lead to increased dilution for common shareholders if the stock price declines. However, the immediate infusion of $2.5 million is a critical liquidity event for a company with a market capitalization of approximately $3.5 million, providing essential operational runway.